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ABSTRACT 
We introduced a methodology to efficiently exploit natural-language expressed biomedical knowledge for repurposing existing 
drugs towards diseases for which they were not initially intended. Leveraging on developments in Computational Linguistics and 
Graph Theory, a methodology is defined to build a graph representation of knowledge, which is automatically analysed to discover 
hidden relations between any drug and any disease: these relations are specific paths among the biomedical entities of the graph, 
representing possible Modes of Action for any given pharmacological compound. These paths are ranked according to their 
relevance, exploiting a measure induced by a stochastic process defined on the graph. Here we show, providing real-world examples, 
how the method successfully retrieves known pathophysiological Mode of Actions and finds new ones by meaningfully selecting and 
aggregating contributions from known bio-molecular interactions. Applications of this methodology are presented, and prove the 
efficacy of the method for selecting drugs as treatment options for rare diseases. 
 
 
In pharmaceutical research the subject of drug repurposing is 
rapidly raising significant interest. Repurposing means redirection 
of clinically advanced or marketed products into certain diseases 
rather than in the initially intended indications. A significant 
advantage of repurposing drugs is their demonstrated clinical 
pharmacological efficacy and safety profile. Repurposing is 
especially interesting in the area of life-threatening Rare or Orphan 
diseases with high unmet medical need. The hypothesis for drug 
repurposing is based on the drugs’ side effects profiles, indicating 
interaction with more than one cellular target. These pathway 
interactions open up the opportunity to exploit existing medicines 
towards other diseases. 
Extensive data sets describing drug effects have been published 
globally, resulting in a huge amount of information publically 
available in large on-line collections of bio-medical publications 
such as PubMed (http://www.ncbi.nlm.nih.gov/pubmed/). 
This is an opportunity for literature-based scientific discovery; 
see [1], [2] and [3]. However, important pieces of information 
regarding chemical substances, biological processes and pathway 
interactions are scattered between publications from different 
communities of scientists, who are not always mutually aware of 
their findings. In order to generate a working hypothesis from such 
a body of literature, a researcher would need to read thoroughly all 
the relevant publications and to pick among them the relevant 
items of information. Search engines help scientists in this 
endeavour, but are unable to semantically aggregate information 
from different sources, leaving all the initiative to researchers; 
complex relation-focused and graph-like representations 
(ontologies) have been extensively produced and used to fill the 
gap, since their introduction for the Semantic Web; see [4] and [5]. 
Yet ontologies need to be man-made and they are difficult to 
integrate each other and to maintain; see [6]. 
Here we propose an approach to literature-based research based 
on the distributional hypothesis of linguistic theory (see [7] and 
[8]) - whose analysis relates the statistical properties of words 
association to the intrinsic meaning of a concept - and network 
theory (see [9, 10, 11]) - a collection of versatile mathematical 
tools for representing interrelated concepts and analyse their 
connections structure. 
Main aim of this work is to provide a methodology for creating 
network knowledge representations, capturing the essential entities 
occurring in a variety of publications and connecting them into a 
graph whenever they co-occur in a given sentence. The knowledge 
graph thus created can then be analysed in order to identify and 
rank statistically relevant indirect connections among prospect 
medicines and diseases. We show that with a suitable set of 
concepts, specifically compiled in a dictionary, the linked 
biochemical entities in the network can be connected along paths 
that mimic a chain of reasoning and lead to prospect inferences 
about the mechanism of action of a chemical substance in the 
pathophysiology of a disease. 
In particular, the proposed method consists of two steps: in the 
first step biomedical papers are collected and submitted to semantic 
analysis in order to retrieve co-occurrences and compute their 
similarity; in the second step the knowledge graph, which has been 
implicitly defined, is analysed to find paths among peptides and  
 
rare diseases using techniques derived from the network theory of 
complex systems. 
 
INFORMATION RETRIEVAL: TEXT SEARCH 
In the field of linguistics it is commonly accepted that the 
meaning of a word must be inferred by examining its occurrences 
over large corpora of text. Adopting this perspective (see [12] and 
[13]), one can say that the meaning of a word ultimately depends 
on the words it mostly goes along with: this is the basis of the so-
called “Distributional Hypothesis” introduced by Firth in 1957. 
The general idea shows that there is a correlation between 
distributional similarity and meaning similarity, which allows 
exploiting the former in order to derive the latter. This hypothesis 
has its shortcomings and intellectual difficulties as an effective 
definition method. A word can appear often alongside its opposite; 
if it has many meanings can co-occur with widely different sets of 
words and its usage may vary with the time (and within different 
corpora). Nonetheless the focus on the connections among words 
is suggestive, because one can imagine plotting them in a graph in 
a sort of network of words. The network representation provides 
new depth to the original linguistic idea because it suggests 
focusing not only on the relations of a word with those it materially 
co-occurs with – its nearest neighbours in the graph – but with 
every other word in the network, even those indirectly connected. 
The meaning of a word is suddenly revealed as something 
depending on the whole and not on the word itself: in the lingo of 
complex systems the meaning of a word is an emergent property of 
the language; see [14] and [15]. 
If this graph of words is transformed into a graph of concepts – 
thereby crossing the boundary between linguistics and semantics – 
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a network of biomedical entities is obtained, where closeness 
implies a strong tendency to be connected through predicates. 
Hopping through this network and drawing a path between any two 
non-adjacent concepts can be interpreted as suggesting a possible 
sentence that has never actually been uttered but that can implicitly 
carry a new and correct idea. 
Moreover, it is possible to augment the connection strength 
between two concepts with the frequency of their co-­‐occurrence, 
therefore introducing a measure of similarity among concepts, and 
thus gaining a new tool to gauge the “likeliness” of a relation. This 
is because highly co-occurring concepts most likely represent 
tightly bound concepts, if not the same one; the path between two 
concepts is then also endowed with a similarity weight opening the 
door to statistical analysis and ranking.  
A dictionary, conceived as a list of synonyms, is implemented 
to transform words into concepts and to work around the 
disambiguation issue; see [16]. The resolution of synonyms in 
biology and medicine is well known because there are several 
names for the same meaning – e.g. the disease Sarcoidosis is also 
known as Morbus Boeck, or as Besnier-Boeck-Schaumann disease. 
In the dictionary a list of relevant concepts is defined, comprising 
peptides, rare diseases and other biological entities such as 
chemical compounds, proteins, receptors, enzymes, hormones and 
physiological entities (e.g. cells, organs, tissues, pathways, 
processes). For each of these concepts a variety of acronyms, 
synonyms and other identifying phrases – including common typos 
and language-related different spellings – are collected to be 
searched for in the papers. Of course different concepts may share 
some of the identifying expressions. This is the polysemy problem 
(see [17]), i.e. the capacity for a word or a phrase to have multiple 
meanings. This is a very complex problem in its generality and, 
although the scientific lingo is quite precise, the methodology 
provides a disambiguation algorithm, which is a version of the 
Lesk algorithm (see [17]), to increase precision in concept 
detection. 
Whenever disambiguation fails, we have chosen to keep both 
the possible concepts: this option reduces precision but maximizes 
recall – i.e. the quantity of relevant concepts that are retrieved. 
Many other errors in the detection of co-occurrences arise beyond 
the ones due to failed disambiguation: a sentence boundary may be 
misplaced, one of the occurrences may be a false positive or the 
occurrences may be just part of a list (and therefore not 
semantically related). It is expected though that as more and more 
papers are analysed the meaningful co-occurrences will outgrow 
the spurious ones: in fact “real” co-occurrences are repeated 
consistently as more and more literature is considered, while 
spurious ones become statistically insignificant because the same 
concept is linked randomly to a great number of other concepts. In 
a figurative manner we may think of a “noise” in the co-occurrence 
detection that becomes negligible as a large number of papers are 
considered.  
The proposed methodology (Fig. 1) requires that every paper is 
broken into its constituent sentences and all occurrences of 
dictionary concepts in them is searched for and registered. This 
kind of search is carried out either in the whole text or, in principle, 
in any subset of it. We have chosen the sentence as the text unit to 
perform the search on to better conform to the distributional 
hypothesis. 
As more and more sentences (and papers) are analysed, more 
and more co-occurrences are found. Eventually, when all co-
occurrences have been retrieved the basic elements are available to 
build the knowledge graph. The nodes of this graph are the entities 
(concepts) previously defined in the dictionary. A link between two 
nodes exists if a co-occurrence, involving their corresponding 
entities, is detected in a sentence. Repeated co-occurrences 
between the same entities proportionally increase the weight of the 
link. Therefore this weight is the co-occurrence frequency. 
For the purpose of building a knowledge graph dealing with 
peptides, the related biological processes and the domain of a 
subset of rare diseases, three million PubMed paper abstracts have 
been elaborated, out of a total of more than 20 million, with a 
dictionary of 1606 concepts (127 peptides, 300 diseases and 1179 
other biological entities). These are the N vertices of the graph in 
Fig. 2a. 
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Figure 1 |Conceptual outline of the knowledge graph building process. (a.) Every document is split into its constituent sentences and 
each of them is scanned to identify expressions registered on the dictionary. In the figure, two sentences are highlighted and the matching 
expressions are enclosed in coloured boxes. Every one of these expressions is associated to a concept in the dictionary. (b.) The concepts co-
occurring in a sentence are connected pairwise. A sentence is therefore abstracted as a complete graph where the occurring concepts are the 
nodes and a single co-occurrence is a link. The weight of a link is increased if more instances of the same co-occurrence are present. (c.) The 
sentence graphs are then merged in such a way that each node (concept) appears only once in the graph. In the figure it is evident that the 
«LAM» node (abbreviation for Lymphangioleiomyomatosis – a rare disease) appears in every graph and the «Lung» node in two of them. 
(d.) The result of the merging is a new graph – which is no more complete – where the weight of the link is associated to the frequency of the 
same co-occurrence. 
 
A single sentence may, of course, contain more than one co-
occurrence between concepts, depending on the number of 
concepts it contains: for a sentence containing N distinct concepts 
exactly N(N-1)/2 co-occurrences are defined, as every concept co-
occurs once with every other. 
The resulting network is sparse with a small number of links 
(158,428) compared to the complete graph (12.7%) but, 
nonetheless, only 30 concepts are not connected to the giant 
component of the network, thus comprising 1576 nodes (98.13% of 
the total). The diameter of this network is 4 with an average path 
length (see [9,11]) of 1.95. It is observed that the graph contains 
hubs interpreted as physiological processes typical of diseases (e.g. 
inflammation, proliferation, necrosis), immune system-related 
items (e.g. white blood cells, cytokines) and the major organs – 
especially the ones dealing with chemical elaboration of drugs (e.g. 
kidney, liver). 
A number of direct connections of “peptides – diseases” are 
present, such as ANGIOTENSIN – SARCOIDOSIS or 
ANGIOTENSIN – DIABETIC NEPHROPATHY (see Fig. 2b). 
The relations between those peptides and diseases are already 
known as we expected on the ground that they appear together in a 
predicate. Indeed, Angiotensin is known to worsen Sarcoidosis 
symptoms, while it is of aid in diabetic nephropathy. These 
features are interpreted as a positive feedback on the 
meaningfulness of the knowledge graph. 
 
ANALYSIS OF THE KNOWLEDGE GRAPH 
Once the Knowledge Graph is built, we are in the position to 
analyse it in order to highlight new scientifically analysable 
relations between a peptide and a rare disease. We search for 
indirect relations in the network (Fig. 2a) and therefore for a path 
(see [9,11]) between a peptide and rare disease (Fig. 2b). Since all 
nodes in the network are connected, these paths always exist: the 
challenge is to rank them (in order to find the most significant 
ones) and to explore and choose those paths that suggest 
understandable and yet non-trivial inferences. 
Shorter paths must be considered more relevant, as more steps 
introduce new levels of indirection and magnify the effects of 
randomness and noise. Yet the paths cannot be too short, because 
they must be “verbose” enough to suggest a rationale to indicate 
the biological Mechanisms of Action (MoA), i.e. a specific 
biochemical interaction through which a drug substance produces 
its pharmacological effect amongst molecular targets like cell 
receptors, proteins or enzymes; in other words the MoA explains 
why and how a drug substance works. Specifically, when dealing 
with peptides, the MoA, that we aim to replicate, is the one where a 
peptide binds to its specific receptors, thus activating or 
a.	   b.	  
c.	   d.	  
4	  
	  
modulating a physiological process involved in the disease. To 
achieve such characteristics, we consider specific interactions 
(links) among nodes, filtering out unwanted information. For 
instance, a peptide may be connected to any node but since we look 
for mechanisms of actions, only links in the form of peptide–cell 
receptor are allowed and therefore considered in the graph. 
Similarly, a receptor can be either involved in a pathway or 
influence directly a biological process, thus only links in the form 
cell receptor–process or cell receptor–protein are allowed. 
 
From the mathematical perspective, co-occurrences define the 
coefficients of the similarity matrix A representing the weighted 
graph. Through a suitable normalization of A we are able to find a 
probabilistic interpretation for the link weights. Specifically, 
posing 𝑤!" = 𝑎!"𝑎!"!  
where 𝑎!" is the i,j element of the similarity matrix, which is 
zero if the vertices i,j are not directly connected and equal to the 
edge weight otherwise. Therefore, the components 𝑤!" can be 
interpreted as the conditional probability 𝑝(𝑖|𝑗) of finding concept i 
in a sentence containing concept j. Since the coefficients of the 
matrix W are in the range (0,1], we can also introduce a 
dissimilarity measure  𝑑!" = −log  (𝑊) 
which is correctly defined in the range 𝑑!" ∈ 0,∞  and, 
oppositely to weights returns larger values for smaller similarities. 
This distance representation allows immediate application of the 
available algorithms for computing shortest paths (see [11]). 
Moreover, shortest paths maximize the sum of link weights, 
but strong indirect connections between a given peptide and a 
given disease may arise also from a set of paths which are smaller 
in weight but that contribute in larger numbers. 
The methodology considers all paths connecting the two concepts 
and uses the abundance and redundancy of these paths, together 
with their weights, as a measure of the strength of the overall 
relation between the concepts. 
 
 
 
  
a                  b 
Figure 2 | Paths identification and selection. (a.) This figure shows a version of the graph – simplified for illustration purposes – built 
focusing onto 300 concepts and with 200,000 documents. (b.) This figure shows three automatically retrieved and meaningful paths, 
identifying three – out of five – prospect candidate peptides for sarcoidosis. The paths are depicted in a further simplified version of the 
graph obtained from the first one by filtering out nodes not relevant to the paths. 
 
This can be achieved by measuring the average number of 
time-steps required to go from one vertex to the other in the 
network, assuming that a walker is moving at random and that at 
each discrete time-step it jumps from a vertex to one of its 
neighbours with a probability which depends on the number of 
available links and to their weights. This random walker produces 
a distance that is a function of both the length and the abundance of 
paths. 
Intuitively, imagine two nodes connected by one short (one 
step) path and many longer ones. A random walker trying the route 
many times will tread the longer paths more often therefore 
perceiving a “long” distance. Instead, if the end points are 
connected with a lot of medium-sized paths, the walker will tread 
those most of the times and thus perceiving a distance shorter than 
the previous one. A common-world example for conveying this 
idea: imagine a drunkard trying to go home. He is likely to make 
many mistakes at the crossroads effectively selecting the next lane 
at random. He is more likely to get home sooner if many roads 
converge to his destination rather than if only a short one goes 
there and the others lead astray. 
The random walk distances can be computed by pure algebraic 
means. The computation is carried out defining a vector, where 
each component is the likelihood that at a given time a random 
walker is on a given node. The step-by-step evolution of this vector 
is a representation of the shifting distribution of these walkers in 
the nodes in their random wandering. 
The probability to walk from vertex i to vertex j is defined in 
the random walk theory by the transfer matrix P, computed from 
the similarity matrix A with the formula: p!" = a!"a!"!                       𝑖, 𝑗 = 1,… ,𝑁 
which is exactly the matrix we have previously denoted W. It 
has been shown (see [18]) that the random walk distances of two 
nodes i and j are given by the formula: 𝑑 𝑖, 𝑗 =    1𝐼 − 𝐵(𝑗) !"!!!!  
where I is the identity matrix and B is a square matrix identical 
to P having posed 
 𝐵(𝑗)!" = 0      ∀𝑖  .   
The random walk distance built this way is non-symmetric, but 
for our purposes we symmetrise it by taking the average of the two 
directions. 𝑑! 𝑖, 𝑗 = !! 𝑑 𝑖, 𝑗 + 𝑑(𝑗, 𝑖)  
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This distance defines an implicit ranking measure for each 
couple of distinct nodes and therefore between any peptide-disease 
couple. 
Such a measure can be interpreted as the probability of finding 
that path, and thus the MoA, within the document base. 
 
RESULTS 
In this paper we show examples of rationales produced by our 
methodology with regard to a) the granulomatous disease 
Sarcoidosis and its pulmonary pathology, and b) Imatinib, a 
targeted-therapy agent against cancer cells, well known for its 
apoptosis action. 
Sarcoidosis is a disease in which abnormal collections of 
chronic inflammatory cells form as nodules (granulomas) in 
multiple organs. Sarcoidosis is present at various level of severity 
in all-ethnic and racial groups and is mainly caused by 
environmental agents in people with higher genetic sensitivity. The 
disease is a chronic inflammatory disease that primarily affects the 
lungs but can affect almost all organs of the body. Sarcoidosis is a 
complex disease displaying incorrect functionalities within 
immune cells, cytokines, and antigenic reactions; see [19]. Fig. 3 
shows a subgraph of the knowledge network comprising the 
concepts related with Sarcoidosis. 
We were interested in using peptides to treat Sarcoidosis. 
Therefore a number of rationales have been obtained from a pool 
of peptides against sarcoid pathologies, and the most relevant 
findings are listed below, ranked according to the random walk 
distance: 
1. VIP – VIPR1 – INFLAMMATION – SARCOIDOSIS 
2. α-MSH – HGFR – INFECTION – SARCOIDOSIS 
3. CNP – NPRB – GUANYLIN_CYCLASE – 
INFLAMMATION – SARCOIDOSIS 
 
 
Figure 3 | The Sarcoidosis knowledge network. A portion of the knowledge network showing the neighbourhood of Sarcoidosis. The 
figure is intended as a bird-eye view of the entities the system detected as related with Sarcoidosis 
 
1. The Match VIP – SARCOIDOSIS 
Vasoactive Intestinal Peptide - VIP (also known as Aviptadil), 
is an endogenous human peptide. It is predominantly localized in 
the lungs where it binds specific receptors (VPAC-1, VPAC-2), 
which transform the signal into an increased production of 
intracellular cyclic adenosine monophosphate (cyclic AMP or 
cAMP), as well as into the inhibition of translocation of NF-κB 
from cytoplasm into the nucleus. This process regulates the 
production of various cytokines responsible for the inflammatory 
reaction, such as TNF-α. Hence, VIP is responsible for preventing 
or attenuating a wide variety of exaggerated pro-inflammatory 
activities; see [20]. 
The path in Fig. 4 shows that VIP is affecting the inflammation 
processes related to Sarcoidosis. 
The scientific evidence clearly suggests VIP as a potential 
treatment option for Sarcoidosis: the system has been able to 
retrieve the main receptor of VIP and its relevance in the 
inflammation process. 
 
 
 
Figure 4 | The VIP – SARCOIDOSIS path and other closely 
related concepts. 
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2. The Match ALPHA-MSH – SARCOIDOSIS 
α-Melanocyte Stimulating Hormone (α-MSH) is an 
endogenous peptide originally described for stimulating 
melanogenesis, mainly for the pigmentation of the skin. Later it 
gained roles in feeding behaviour, sexual activity, immune 
responses, inflammation and fibrosis. Upon binding to its specific 
cell surface receptors it increases production of cAMP in the target 
cells and triggers four signalling pathways leading to the disruption 
of the transcription of several pro-inflammatory mediators genes; 
see [20]. 
In addition, α-MSH also regulates the MET proto-oncogene 
expression in both melanoma cells and in normal human 
melanocytes. The MET proto-oncogene encodes for the 
Hepatocyte Growth Factor Receptor (HGFR) that is involved in 
melanocyte growth and melanoma development; see [21]. 
There is evidence of interrelation between Epstein-Barr Virus 
(EBV) infection and MET proto-oncogene expression, and at date 
several infection agents have been suggested to have an implication 
as cause of Sarcoidosis. 
A role for a transmissible agent is also suggested by the finding of 
granulomatous inflammation in patients without Sarcoidosis who 
received heart transplantation from donors who had Sarcoidosis; 
see [22] and [23]. 
The system sees both these processes (as apparent from Fig. 5), 
assigning a better ranking to the second one. α-MSH is another 
candidate for the treatment of sarcoid pathology due to this double 
action. 
 
 
Figure 5 | The α-MSH – SARCOIDOSIS path and other closely 
related concepts. 
 
 
 
3. The Match CNP – SARCOIDOSIS 
CNP (C-type Natriuretic Peptide) is a human peptide, which 
elicits a number of vascular, renal, and endocrine activities, 
regulating blood pressure and extracellular fluid volume. When 
CNP binds to its receptor, NPRB, on the cell surface it activates a 
cell signalling through a Guanyl cyclase that increases intracellular 
cGMP level activating specific pathways ultimately modifying 
cellular functions. cGMP is known for its potent vasodilatory 
action in pulmonary vessels. Depending on the tissues involved, 
however, some of its effects are directly opposite to those of 
cAMP, which is a potent inhibitor of proinflammatory tumor 
necrosis factor (TNF-α) synthesis; see [24].  
The inference subtended by the path in Fig. 7 is sound and 
correctly traces a biological process. Yet CNP is not considered a 
treatment option for Sarcoidosis because of its potential negative 
side effects profile due to its systemic vasodilatory characteristics.  
 
 
 
Figure 6 | The CNP – SARCOIDOSIS path and other closely 
related concepts. 
4. The Match Imatinib – Creutzfeldt-Jakob disease 
Imatinib (commercialized under the name GLEEVEC) is a 
rationally designed pyridylpyrimidine derivative, and a highly 
potent and selective competitive tyrosine kinase inhibitor, 
especially effective in the inhibition of kinases c-Abl (Abelson 
proto-oncogene), c-kit, and PDGF-R (platelet-derived growth 
factor receptor); see [25] and [26]. These kinases are enzymes 
involved in cellular signal transduction processes, whose 
dysregulation may lead to malfunctioning of cells and disease 
processes, as exemplified in a variety of hyperproliferative 
disorders and cancers. Imatinib has been regulatory approved for 
chronic myelogenous leukemia (CML), gastrointestinal stromal 
tumors (GISTs), aggressive systemic mastocytosis (ASM), 
hypereosinophilic syndrome (HES), chronic eosinophilic leukemia 
(CEL), dermatofibrosarcoma protuberans, and Acute 
Lymphoblastic Leukemia (ALL).  
Exploiting our methodology we looked for rationales for the 
redirection of Imatinib; on the basis of the results of the stochastic 
measure, the system indicates the neurodegenerative transmissible 
spongiform encephalopathies – exemplified by the Creutzfeldt-
Jakob disease (CJD) – as promising targets for this drug. 
Transmissible spongiform encephalopathies are caused by the 
aberrant metabolism of the prion protein (PrP). Prions are 
seemingly infectious agents without a nucleic acid genome. Prion 
diseases belong to the group of neurodegenerative diseases 
acquired by exogenous infection and have a long incubation period 
followed by a clinical course of progressive dementia, myoclonal 
ataxia, delirious psychomotor excitement, and neuronal death; see 
[27]. 
Moreover, the system selects the path (see Fig. 7) that indicates 
the kinase c-Abl effect on cell-apoptosis as key MoA for 
redirecting Imatinib towards CJD. In fact, the c-Abl tyrosine kinase 
is found to be over-activated in neurodegenerative diseases like 
Alzheimer's disease and Parkinson's diseases, and overexpression 
of active c-Abl in adult mouse neurons results in 
neurodegeneration and neuroinflammation; see [28]. There is clear 
experimental evidence that activation of c-Abl leads to neuronal 
cell death and neuronal apoptosis in experimental Creutzfeldt-
Jakob disease; see [29]. Imatinib has been shown to prevent c-Abl 
kinase induced apoptosis in animal models of neurodegeneration; 
see [30]. Finally, Imatinib was shown to clear prion-infected cells 
in a time and dose-dependent manner from misfolded infectious 
protein without influencing the normal biological features of the 
healthy PrP, and Imatinib activated the lysosomal degradation of 
pre-existing misfolded PrP; see [31]. This provides a sound 
rationale for the proposed redirection. 
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Figure 7 | Imatinib (GLEEVEC) – Creutzfeldt-Jakob Disease 
path and other closely related concepts 
The system indicated also Imatinib as a treatment option for 
pulmonary arterial hypertension (PAH), via its potent inhibitory 
effect on the PDGF Receptor (PDGF-R). For the indication PAH, 
the drug is however not approved. 
 
CONCLUSION 
A double-layer methodology is presented, consisting of 
semantic analysis – leveraging on developments of Computational 
Linguistics – and graph analysis – exploiting Graph Theory and 
Stochastic Process Theory tools. This methodology has allowed the 
screening of more than 3 million abstracts from PubMed-published 
biomedical papers and the detection of relevant concepts identified 
by dictionary-defined expressions; concepts have been mapped as 
nodes of a graph, whose links are defined by co-occurrence of 
concepts across roughly 30 million of sentences. Specifically, the 
pathophysiological connections between peptides and diseases 
have been detected in order to provide inferences for biomedical 
rationales for drug repurposing. 
The proposed methodology provides an effective instrument to 
detect different MoAs of peptides and drugs; though it may not 
capture the full-detail of the MoAs, it succeeds in making them 
recognizable by a short chain of biomedical entities. Moreover, the 
graph representations of biomedical knowledge seen above 
produces a sound and meaningful representation of the many 
interrelated concepts of the biomedical discipline; such 
methodology successfully allows both the validation of existing 
rationales and the discovery of new ones, a feat usually left to 
serendipity and intuition. We have translated the scientific 
rationales in relevant clinical trial settings into new potential 
treatment options for the affected patients in Sarcoidosis. 
We have looked for experimental evidence of our findings on 
sarcoid pathologies: we have chosen the peptides VIP and α-MSH 
for drug repurposing. In an open clinical phase II study, we treated 
20 patients with histologically proven Sarcoidosis and active 
disease with nebulized VIP for 4 weeks. This study is the first to 
show that VIP has clear, positive, immune-regulatory effects in 
sarcoid patients without any obvious side effects and without 
systemic immuno-suppression. VIP should therefore be developed 
as an attractive therapeutic option for patients with pulmonary 
Sarcoidosis; see [32]. In parallel, we have initiated a clinical ex-
vivo trial to prove α-MSH in a sarcoid pathology. Preliminary data 
clearly suggest a beneficial outcome of the experimentation, clearly 
suggesting α-MSH as another potential treatment option for this 
pathology. 
Moreover, the case for Imatinib as a treatment option for the 
Creutzfeldt-Jakob disease shows how the system is able to produce 
a sound scientific rationale also for non-peptide drugs and with a 
mechanism of action quite different from the others, thus proving a 
much wider applicability. 
Results are more noteworthy if the relative slimness of the 
dictionary is taken into account. Better representations are to be 
expected defining more detailed and more comprehensive 
dictionaries. Furthermore, Graph Theory tools provide quite an 
interesting arsenal of instruments that analyse a complex network 
of nodes (biological and medical concepts) and highlight hidden 
inferences across biochemical compounds, clinical data and 
medical concepts.  
As it is apparent from this presentation the specific field of 
application enters the methodology in the broad selection of the 
document base and in the definition of the dictionary: the inner 
mechanism of knowledge representation and analysis is quite 
independent of it. 
We would like to stress that here we have provided only very 
general characterization of the knowledge network and focused 
onto very well consolidated tools of analysis. But the field of 
complex networks is currently under massive development, 
providing ever more subtle indicators of graph features and related 
techniques of analysis. We therefore think that our reliance on 
graph representation poses this method in the best position to 
exploit this development and may well prove to make it 
mainstream in the field of information retrieval. Further 
investigations will concern the use of clustering methods to link 
groups of other molecules with groups of diseases [33,34]. 
 
This methodology can be applied to other fields: it can be 
extended over broader biomedical research, transcending peptides, 
to study other chemical compounds and also focusing on diseases 
or other pathologies other than rare ones. Ultimately, it can be 
applied to any field of research – even outside natural science – 
provided that a suitable amount of literature is available and that 
the main issue be the association of a great number of particular 
facts and observation that do not yet fit into an already understood 
and comprehensive scheme.  
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